Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer.

Abstract

This pharmacologic strategy permits the selective and rapid delivery of extremely high doses of DDP to head and neck carcinomas with minimal procedural complications, low systemic toxicity, and high tumor response rates.